Prolymphocytic leukemia (PLL) is a rare subtype of leukemia that affects the B-cells or T-cells. It is characterized by the uncontrolled growth of lymphocytes in the bone marrow, blood, and other organs. PLL of B-cell type is a less common form of PLL, accounting for less than 20% of all cases.
When a patient is diagnosed with PLL, the primary goal of treatment is to achieve remission. Remission is defined as the absence of cancer cells in the blood and bone marrow. Unfortunately, not all patients with PLL of B-cell type achieve remission, even after receiving treatment.
There are several factors that can affect a patient's ability to achieve remission, such as the stage of the disease, the age of the patient, and the presence of other medical conditions. Patients who have a high number of cancer cells in their blood and bone marrow, for example, may be less likely to achieve remission than those with a lower number of cancer cells.
Patients who do not achieve remission may experience a range of symptoms, including fatigue, weakness, and an increased risk of infection. They may also be at risk of developing other complications, such as bleeding or anemia. It is important for patients who have not achieved remission to work closely with their healthcare team to manage their symptoms and monitor their condition.
Patients who do not achieve remission may also be candidates for clinical trials or new treatments that are currently being developed. By participating in clinical trials, patients may have access to new therapies that have not yet been approved by the FDA.
In conclusion, PLL of B-cell type not having achieved remission is a challenging condition that requires ongoing management and support. Patients who have not achieved remission should work closely with their healthcare team to manage their symptoms and monitor their condition. With proper care and treatment, patients can continue to lead fulfilling lives despite their diagnosis.
To see full information about treatment please Sign up or Log in